0001209191-23-033020.txt : 20230530 0001209191-23-033020.hdr.sgml : 20230530 20230530185757 ACCESSION NUMBER: 0001209191-23-033020 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230525 FILED AS OF DATE: 20230530 DATE AS OF CHANGE: 20230530 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Socks David A CENTRAL INDEX KEY: 0001378847 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39094 FILM NUMBER: 23978394 MAIL ADDRESS: STREET 1: C/O CADENCE PHARMACEUTICALS, INC. STREET 2: 12481 HIGH BLUFF DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Phathom Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001783183 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 824151574 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 CAMPUS DRIVE, STREET 2: SUITE 102 CITY: FLORHAM PARK STATE: NJ ZIP: 07932 BUSINESS PHONE: (877) 742-8466 MAIL ADDRESS: STREET 1: 100 CAMPUS DRIVE, STREET 2: SUITE 102 CITY: FLORHAM PARK STATE: NJ ZIP: 07932 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-05-25 0 0001783183 Phathom Pharmaceuticals, Inc. PHAT 0001378847 Socks David A C/O PHATHOM PHARMACEUTICALS, INC. 100 CAMPUS DRIVE, SUITE 102 FLORHAM PAK NJ 07932 1 0 0 0 0 Common Stock 2023-05-25 4 A 0 9000 0.00 A 9000 D Common Stock 1211346 I David A. Socks 2013 Revocable Trust Common Stock 409.73 I By 401(k) Stock Option (Right to Buy) 11.72 2023-05-25 4 A 0 15000 0.00 A 2033-05-24 Common Stock 15000 15000 D The Restricted Stock Units ("RSUs") were granted on May 25, 2023, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing in service on the Board through such vesting date. /s/ Larry Miller, Attorney-in-Fact for David A. Socks 2023-05-30